Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

DOI Web Site Web Site 1 Citations

Journal

Citations (1)*help

See more

Report a problem

Back to top